Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Lorenzo Ferrando

Assistant Professor

University of Genoa

Italy

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Articles (6)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Collaborators (8)

Simona Francia

Ospedale Policlinico San Martino

ITALY

View details

Higinio Dopeso

Senior Research Scientist

Sloan Kettering Institute

UNITED STATES

View details

Fabio Benfenati

Research Director

Istituto Italiano di Tecnologia

ITALY

View details

Antonio Marra

Research Associate

Sloan Kettering Institute

UNITED STATES

View details

José Manuel Lopes

Chief Pathologist

Centro Hospitalar Universitário do Porto

PORTUGAL

View details

Elisabetta Munzone

Director

European Institute of Oncology

ITALY

View details

Gian Paolo Dagrada

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

Federico Carbone

Professore Associato

Università degli Studi di Torino

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Lorenzo Ferrando

Research Interests

Make your next move.

Explore related searches

Articles (6)

Influence of medical educational background on the diagnostic quality of ChatGPT‐4 responses in internal medicine: A pilot study

Genomic landscape of breast cancer in elderly patients

CDKN2A homozygous deletions and TSC2 somatic mutations in metastatic pancreatic neuroendocrine tumors

Noradrenergic control of bone marrow and thymus by AgRP neurons is impaired in experimental multiple sclerosis

Biological modifications of the immune response to COVID-19 vaccine in patients treated with rituximab and immune checkpoint inhibitors

ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).

Collaborators (8)

Simona Francia

Higinio Dopeso

Fabio Benfenati

Antonio Marra

José Manuel Lopes

Elisabetta Munzone

Gian Paolo Dagrada

Federico Carbone

Make your next move.